Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.
about
Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.Precision, accuracy, and resolution-Dose selection of oral anticancer agents.
P2860
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Activity of erlotinib when dos ...... targeted therapy development.
@en
type
label
Activity of erlotinib when dos ...... targeted therapy development.
@en
prefLabel
Activity of erlotinib when dos ...... targeted therapy development.
@en
P2093
P2860
P356
P1433
P1476
Activity of erlotinib when dos ...... targeted therapy development.
@en
P2093
Abigail A Santos
Benjamin L Lampson
Danie Paul
Geoffrey R Oxnard
Mizuki Nishino
Suzanne E Dahlberg
P2860
P356
10.1002/CNCR.30270
P407
P50
P577
2016-08-15T00:00:00Z